FindTrial
Sign In

Diagnostic value of ACR TI-RADS stratification system combined with BRAF V600E gene in thyroid Bethesda category III nodules

Diagnostic value of ACR TI-RADS stratification system combined with BRAF V600E gene in thyroid Bethesda category III nodules

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101444
Enrollment
Unknown
Registered
2025-04-24
Start date
2025-04-25
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid nodules

Interventions

Gold Standard:Pathologic diagnosis
Index test:ACR TI-RADS stratification system combined with BRAF V600E geneBethesda ?

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.FNA cytopathology results were Bethesda class III; 2.BRAF V600E gene test information available; 3.Surgical pathology available or re-puncture biopsy with a clear pathologic diagnosis; 4.Detailed documented information on ultrasound with thyroid nodules, complete with high-resolution ultrasound images;

Exclusion criteria

Exclusion criteria: 1.Thyroid lobe partially removed for malignant tumor prior to FNA; 2.Incomplete ultrasound image information;

Design outcomes

Primary

MeasureTime frame
sonographic features;BRAF V600E gene;Sensitivity;Specificity;Accuracy;—

Countries

China

Contacts

Public Contactguo yan li

The First Affiliated Hospital of Army Medical University

guoyanli71@aliyun.com+86 13608351873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026